Bruce Power receives regulatory approval to produce medical Lu-177

September 29, 2021, 9:27AMNuclear News
The Bruce nuclear power plant in Ontario, Canada. (Photo: Bruce Power)

Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to begin the production of lutetium-177, becoming the first power reactor globally to commercially produce the medical radioisotope. Isogen, a joint venture between Framatome and Kinectrics, will produce Lu-177 at Bruce’s eight-unit CANDU nuclear power plant in Ontario, Canada, using Isogen’s isotope production system (IPS).

To continue reading, log in or create a free account!

Related Articles

Workshop on SMRs scheduled for Ottawa

January 29, 2024, 7:00AMNuclear News

The OECD Nuclear Energy Agency is hosting a workshop on the economics of small modular reactors in Ottawa, Canada, on February 27, 2024.The workshop will be an in-person event, with no hybrid...